Related Experiment Video

Updated: Aug 20, 2026

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

Sudden death in Prader-Willi syndrome during growth hormone therapy

Michele Sacco1, Girolamo Di Giorgio

  • 1Division of Paediatrics, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. micheleacco2001@yahoo.it

Hormone Research
|December 8, 2004
PubMed

Insights

A child with Prader-Willi syndrome (PWS) experienced sudden death after growth hormone (GH) therapy. This case highlights the need for further studies on the potential link between GH therapy and sudden death in PWS patients.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Genetics

Background:

  • Prader-Willi syndrome (PWS) is a complex genetic disorder associated with various health issues, including obesity.
  • Growth hormone (GH) therapy is sometimes used in managing PWS, but its safety profile requires ongoing evaluation.
  • Sudden death has been a concern in PWS populations, with potential contributing factors under investigation.

Observation:

  • This report details a case of a 3-year-old child with PWS who died suddenly 7 months after starting GH therapy.
  • The child presented with severe obesity but no prior respiratory issues.
  • This event occurred despite the absence of respiratory compromise, a factor often linked to sudden death in PWS.

Findings:

  • The sudden death of this PWS patient following GH therapy raises questions about a potential association.
  • The case suggests that GH therapy might be a factor in sudden death, even in PWS individuals without respiratory problems.
  • This contrasts with previous suspicions that primarily focused on respiratory issues in PWS patients undergoing GH treatment.

Implications:

  • Further epidemiological studies are crucial to determine the frequency of this potential causal link between GH therapy and sudden death in PWS.
  • Understanding the pathogenesis of sudden death in PWS patients receiving GH therapy is essential for clinical practice.
  • This case underscores the importance of careful monitoring and risk-benefit assessment when initiating GH therapy in children with PWS.

More Related Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...